Prognostic value of LPAR1 expression and methylation in low-grade gliomas: a meta-analysis of TCGA and CGGA datasets and functional validation

作者：Hongmin Chen, Wenyi Liang, Zhang Li, Chenbin Bian, Hongbin Wang, Song Luo, Xin You, Wang Feng, Liang Liang · 发表于：Figshare · 年份：2025 · DOI：10.6084/m9.figshare.c.8281466 · 研究领域：Sphingolipid Metabolism and Signaling、Immune cells in cancer、Peroxisome Proliferator-Activated Receptors

Abstract Background Lysophosphatidic acid receptor 1 (LPAR1) mediates various biological behaviors in physiological and pathological processes. This study aims to comprehensively evaluate the prognostic value of LPAR1 expression and methylation in LGG, and explore their functional effects on tumor progression and immune regulation. Methods The GEO database was used to analyze LPAR1 expression in tumors and normal tissues. The TCGA-LGG and CGGA datasets were used to analyze the expression, methylation, immunity and prognostic significance of LGG. Immune cells and immune pathways were detected by flow cytometry, ELISA and western blot analysis. The role of LPAR1 in LGG was validated by RT-PCR, TUNEL assay, CCK-8 assay, flow cytometry, wound healing assay and transwell assay. Results We included 627 patients who contained complete information required for analysis in the TCGA-LGG and CGGA datasets. Methylation of the LPAR1 promoter suppresses its expression. High methylation levels were associated with better overall survival (OS) and progression-free survival (PFS) (P < 0.05) in LGG. Decreased LPAR1 expression and increased methylation levels were significantly associated with age, histological types and isocitrate dehydrogenase (IDH) mutation status (P < 0.05). Multivariate analysis showed that LPAR1 was an independent prognostic factor for LGG (P = 0.002). Meta-analysis showed that high LPAR1 expression was indeed a poor prognosis for patients’ OS in LGG (HR, 1.06; 95% ...